The Curious Progression of Hepatitis C

Hepatitis C, a serious infection that is passed between people only by blood-to-blood contact was only given its official name in 1989. Before that, as scientists were trying to determine if it was different from the other types of Hepatitis and if so how, it was simply referred to as non-A or non-B Hepatitis. What an odd name for a disease that currently infects at least four million people in the Untied States and over one hundred and seventy million people globally.

Hepatitis C is an odd one because so much of the time it is not obvious when someone has the infection. Seventy percent of those infected show no symptoms, this makes it very hard to diagnose. It is believed that during the acute stage, the first six months, twenty five percent of people who are infected become uninfected for reasons that no one is able to determine.  This is known as spontaneous viral clearance.

For the other seventy five percent of those infected with the Hepatitis C virus, also now as HCV, it becomes chronic.   The only problem with these figures is that they are a bit of a guess.  The number of people that are lucky enough to have a spontaneous viral clearance could be much higher based on the fact that so many people don't realize that they are infected until the HCV has been around for a long time and symptoms start to show. There are no tests that will be able to tell researchers what the exact figures are at this time.

At one time it was common practice to not treat those who were considered to still be in the acute stage. This was because they hoped that by doing nothing it would just go away.  Recent studies are showing that was wrong and that if Hepatitis C is treated early there is a ninety percent success rate. Not only that but the treatment time is cut in half.

Once passed the infection period of six months the Hepatitis C virus now becomes considered a chronic infection.  Interestingly of those who remain untreated it will take thirty percent of them about twenty years to develop cirrhosis of the liver. The next one third will take another ten years on top of that and the last third will take so long that they will die before the liver develops the cirrhosis. There are upwards of one hundred and fifty thousand new cases of HCV each year in the Untied States. People with HIV are very likely to also be infected with HCV as both diseases have similar transmission requirements. Around seventy percent of all intravenous drug users have Hepatitis C.

Research continues on what can be done to control this very serious infection. Unlike Hepatitis A or B there is currently no vaccine.  But recent studies have made some progress and a new vaccine is in the testing stages with human subjects. So far it is having significantly successful results. The studies are continuing. 

Hepatitis news on the Web

Queries irk hepatitis patients (Las Vegas Review-Journal)
It was never the Southern Nevada Health District's intent to embarrass anyone when it determined what questions to ask former patients of two Las Vegas gastroenterology clinics regarding their past risk factors for hepatitis B, C and HIV.

StemCells, Inc. Receives NIH Grant To Pursue Cell-Based Therapeutic For Hepatitis C (Medical News Today)
StemCells, Inc. (Nasdaq:STEM) announced that it has been awarded a $305,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases to research and develop a potential cell-based therapeutic for liver disease arising from infection by the hepatitis C virus (HCV).

Urgent need for action to tackle hepatitis C (icWales)
WALES faces an “explosion” in patients suffering liver failure if nothing is done to improve services for people with hepatitis C, experts have claimed.

Two more die of Hepatitis E (The Monitor)
At least two more people died of Hepatitis E last week in Kitgum, the LC5 chairman, Mr John Bosco Ogwok, has revealed. “Hepatitis E is under control though it killed two people last week.

OctoPlus Has Record Gain as Biolex Buys Drug Rights (Update1) (Bloomberg)
Oct. 6 (Bloomberg) -- OctoPlus NV had a record gain in Amsterdam trading after the Dutch drugmaker dependent on temporary financing said it will get as much as $149 million from Biolex Therapeutics Inc. for rights to a hepatitis C medicine.

HIV, hepatitis tests urged for tattoo parlour clients (Windsor Star)
NIAGARA FALLS - Ontario health officials are urging people who received tattoos or piercings at two southern Ontario parlours this summer to undergo blood tests for HIV and hepatitis, after they were found to have used unsterilized equipment.

Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron(R) in Hepatitis C (Marketwire via Yahoo! Finance)
Biolex Therapeutics, Inc. announced the closing of a $60 million Series D financing led by Clarus Ventures, a leading biotechnology investor, with OrbiMed Advisors participating as a new investor.

Natalie Cole, suffering from hepatitis C, is out of the hospital and resting at home (Minneapolis-St. Paul Star Tribune)
NEW YORK - Natalie Cole, who suffers from hepatitis C, is resting at her Los Angeles home after being released from the hospital earlier this week, Cole's representative said Friday.

Natalie Cole on bed rest after Hepatitis C bout (Reuters via Yahoo! News)
Singer Natalie Cole is resting in bed at her Los Angeles home after being hospitalized in New York last month because of a setback in her battle with Hepatitis C, her spokeswoman said on Thursday.

Cole on bed rest following hepatitis bout (Gulf Daily News)
LOS ANGELES: Singer Natalie Cole is resting in bed at her Los Angeles home after being admitted to a hospital in New York last month because of a setback in her battle with hepatitis.